AR059577A1 - Agente de aceleracion de absorcion del calcio - Google Patents

Agente de aceleracion de absorcion del calcio

Info

Publication number
AR059577A1
AR059577A1 ARP070100597A ARP070100597A AR059577A1 AR 059577 A1 AR059577 A1 AR 059577A1 AR P070100597 A ARP070100597 A AR P070100597A AR P070100597 A ARP070100597 A AR P070100597A AR 059577 A1 AR059577 A1 AR 059577A1
Authority
AR
Argentina
Prior art keywords
calcium
agent
calcium absorption
acceleration agent
gum arabic
Prior art date
Application number
ARP070100597A
Other languages
English (en)
Spanish (es)
Inventor
Hideaki Matsuda
Masahiro Iwaki
Atsushi Kawase
Original Assignee
Veritron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritron Ltd filed Critical Veritron Ltd
Publication of AR059577A1 publication Critical patent/AR059577A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
ARP070100597A 2006-02-17 2007-02-13 Agente de aceleracion de absorcion del calcio AR059577A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77437406P 2006-02-17 2006-02-17
JP2006041158 2006-02-17

Publications (1)

Publication Number Publication Date
AR059577A1 true AR059577A1 (es) 2008-04-16

Family

ID=38042502

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100597A AR059577A1 (es) 2006-02-17 2007-02-13 Agente de aceleracion de absorcion del calcio

Country Status (15)

Country Link
US (2) US20090098222A1 (enExample)
EP (2) EP1986566B1 (enExample)
JP (1) JP5281895B2 (enExample)
KR (1) KR20080103528A (enExample)
CN (2) CN102755374A (enExample)
AR (1) AR059577A1 (enExample)
AT (1) ATE535283T1 (enExample)
AU (1) AU2007215753B2 (enExample)
BR (1) BRPI0708061A2 (enExample)
CA (1) CA2642248A1 (enExample)
MY (1) MY147271A (enExample)
RU (1) RU2428193C2 (enExample)
SG (1) SG169979A1 (enExample)
TW (1) TW200800292A (enExample)
WO (1) WO2007094486A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007039310A1 (de) * 2007-08-13 2009-02-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose
US9144249B2 (en) * 2008-06-23 2015-09-29 Amano Enzyme Usa, Ltd. Enzymatic methods of flavor modification
US10092518B2 (en) 2012-04-10 2018-10-09 Alpina Laudanum Institute Of Phytopharmaceutical Sciences Ag Wet granulation process and granulate material comprising Arabic gum
CN107929313B (zh) * 2017-11-21 2021-02-19 上海金城素智药业有限公司 用于预防和治疗钙缺乏症的天然型牡蛎碳酸钙制剂及其制备方法
IT201900023016A1 (it) * 2019-12-04 2021-06-04 Alesco Srl Formulazioni comprendenti un minerale e un polisaccaride, loro composizioni e loro uso nella supplementazione di detto minerale
GB2637232A (en) * 2024-01-11 2025-07-16 Bios Therapy Physiological Systems For Health S P A A natural matrix mixture for the treatment of bone fragility

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
NZ306211A (en) * 1995-04-07 1998-08-26 Abbott Lab Calcium supplements, in particular beverage concentrates, with vitamin d and a calcium source
US5609897A (en) * 1995-04-07 1997-03-11 Abbott Laboratories Powdered beverage concentrate or additive fortified with calcium and vitamin D
JP4493736B2 (ja) 1995-09-01 2010-06-30 日本水産株式会社 キチンを含有するミネラル吸収促進性組成物およびミネラル吸収促進用添加剤
US5855936A (en) * 1997-03-21 1999-01-05 Nestec S.A. Food fortification
WO1998042210A1 (en) * 1997-03-24 1998-10-01 Maruo Calcium Company Limited Food additive slurry composition and powder composition and food compositions containing these
JPH11313634A (ja) * 1998-03-12 1999-11-16 Internatl Flavors & Fragrances Inc <Iff> 呈味剤とその製造方法
ID24710A (id) * 1998-05-12 2000-08-03 Nutricia Nv Komposisi nutrisi untuk perawatan luka karena tekanan
JP2000026283A (ja) * 1998-07-10 2000-01-25 Nisshin Oil Mills Ltd:The 油性組成物を含有した粉末組成物
US6455082B1 (en) * 1999-04-26 2002-09-24 Nestec S.A. Shelf-stable calcium fortified milk and dairy products
JP2001186863A (ja) * 2000-01-05 2001-07-10 Maruo Calcium Co Ltd 食品添加剤スラリー組成物及びパウダー組成物、及びこれを含有する食品組成物
JP3563343B2 (ja) 2000-11-10 2004-09-08 株式会社東洋新薬 カルシウム利用効率が向上した食物繊維含有食品
JP2002223737A (ja) * 2001-02-02 2002-08-13 Dai Ichi Kogyo Seiyaku Co Ltd カルシウム強化飲料用分散剤、及びカルシウム含有粉末
JP4390428B2 (ja) * 2001-05-01 2009-12-24 株式会社林原生物化学研究所 含カルシウム組織強化剤
DE10127897B4 (de) * 2001-06-08 2006-04-20 Bionorica Ag Manteltablette mit Pflanzentrockenextrakten
US20030203097A1 (en) * 2002-04-24 2003-10-30 The Procter & Gamble Company Acidic compositions comprising protein and fiber and processes of their preparation
US7138151B2 (en) * 2002-11-22 2006-11-21 Unilab Pharmatech, Ltd. Calcium-fortified acidic beverages
JP2004292382A (ja) * 2003-03-27 2004-10-21 Kirin Brewery Co Ltd ミネラル吸収促進剤及び骨粗鬆症用予防及び／又は改善剤
JP2005047820A (ja) * 2003-07-29 2005-02-24 Taiyo Kagaku Co Ltd 整腸用組成物
KR20030078050A (ko) * 2003-09-01 2003-10-04 주식회사 엠에스씨 고분산성 유청칼슘 조성물 및 그 제조방법
CN1833727B (zh) * 2005-03-18 2010-07-28 潘思源 阿拉伯树胶在建立动物模型和降低血胆固醇中的用途
US20070003671A1 (en) * 2005-07-01 2007-01-04 Anglea Timothy A Two-part calcium fortified compositions and methods of making the same
CN101484146A (zh) * 2006-05-23 2009-07-15 奥拉黑尔斯公司 木糖醇锭剂及其用法

Also Published As

Publication number Publication date
ATE535283T1 (de) 2011-12-15
EP1986566A1 (en) 2008-11-05
KR20080103528A (ko) 2008-11-27
EP1986566B1 (en) 2011-11-30
JP2009526748A (ja) 2009-07-23
BRPI0708061A2 (pt) 2011-05-17
AU2007215753A1 (en) 2007-08-23
RU2008137129A (ru) 2010-03-27
CN101431959A (zh) 2009-05-13
EP2298276A1 (en) 2011-03-23
RU2428193C2 (ru) 2011-09-10
CN102755374A (zh) 2012-10-31
AU2007215753B2 (en) 2013-04-18
US20090098222A1 (en) 2009-04-16
WO2007094486A1 (en) 2007-08-23
JP5281895B2 (ja) 2013-09-04
EP2298276B1 (en) 2020-01-15
US20110045014A1 (en) 2011-02-24
MY147271A (en) 2012-11-30
SG169979A1 (en) 2011-04-29
TW200800292A (en) 2008-01-01
CA2642248A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
AR054912A1 (es) Composiciones humectantes bucales, sistemas liberadores que contienen dichas composiciones y metodos para producirlas
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
CL2007003640A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
AR074777A1 (es) Proteinas de union a antigeno
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
PH12013502192A1 (en) Antibodies against human angiopoietin 2
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol &gt; 0,75 y 1
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
AR072003A1 (es) Efectos antitumorales de combinaciones cannabinoides
AR064725A1 (es) Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
HN2006009702A (es) Composicion farmaceutica para el tratamiento del cancer
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
AR059577A1 (es) Agente de aceleracion de absorcion del calcio
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
PH12014500344A1 (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
GT200600106A (es) Agentes endoparasiticidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure